ALCLS.PA Cellectis EURONEXT €3.47 intraday 10 Mar 2026: earnings loom

ALCLS.PA stock jumps 9.81% intraday to €3.47 as traders price in Cellectis S.A.’s upcoming earnings on 12 Mar 2026. The move follows renewed interest in the company’s allogeneic CAR-T pipeline and a mixed sell-side view. Volume sits at 158,359.00 versus an average 304,082.00, signalling selective buying. With EPS at -0.28 and a negative PE of -11.64, investors should focus on clinical updates and cash runway data in the report. This earnings spotlight lays out what could shift the tradeable outlook for ALCLS.PA stock.

ALCLS.PA stock: earnings timeline and expectations

Cellectis (ALCLS.PA) will report results after the US market close on 12 Mar 2026. Market attention will centre on operational guidance, clinical-readout timing for UCART programs, and any updates on partnerships. Analysts expect commentary on revenue drivers and R&D spend. A clear update on trial timelines could trigger a re-rate because the stock trades on program progress rather than near-term profits.

Earnings preview and clinical catalysts

Cellectis runs two segments: Therapeutics and Plants, but investors focus on immuno-oncology assets such as UCART19 and ALLO-501 series. Revenue growth was 53.97% for FY 2024, but net income remains negative with EPS -0.28. Key catalysts in the earnings release include clinical milestone dates, enrolment updates, and partner announcements. Positive trial language could push estimates higher; adverse phrasing could widen volatility.

Financials and valuation snapshot for ALCLS.PA stock

At €3.47, market cap is about €235,889,443.00 with 72,358,725.00 shares outstanding. Price-to-sales is 3.64, price-to-book is 3.78, and enterprise value is €314,813,449.85. The current ratio is 1.49 and debt-to-equity is 0.92, signalling manageable leverage for a clinical-stage biotech. High R&D-to-revenue at about 119.50% highlights the cash burn profile. Valuation still reflects binary clinical outcomes rather than steady cash flow metrics.

Technical and intraday trading snapshot

Intraday range: €3.32 (low) to €3.55 (high). The 50-day average is €3.52 and the 200-day average is €2.89. RSI sits at 40.99, MACD histogram slightly negative, and ATR is €0.22, suggesting moderate volatility. On-balance volume sits near 491,457.00, showing accumulation over recent sessions. Traders watching ALCLS.PA stock should note tighter Bollinger band mids at €3.34, which could lead to a short-term breakout post-earnings.

Meyka AI grade and forecast for ALCLS.PA

Meyka AI rates ALCLS.PA with a score of 69.16 out of 100 — Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €3.30, quarterly €4.06, and yearly €5.60. Versus the current price €3.47, that implies a quarterly upside of 17.01% and a 12-month upside of 61.39%. Forecasts are model-based projections and not guarantees.

Risks and what to watch into earnings for ALCLS.PA stock

Key risks: clinical setbacks, slower-than-expected enrolment, and weak revenue guidance. Rating services published a firm-level score of D+ on 09 Mar 2026, recommending Strong Sell, highlighting valuation and profitability concerns. Cash per share of €1.90 offers some runway but not immunity. Watch language on partnerships, regulatory pathways, and any non-recurring items that could mask core trends.

Final Thoughts

Short-term traders are pricing ALCLS.PA stock for a news-driven move into the 12 Mar 2026 earnings release. The intraday jump to €3.47 on 10 Mar 2026 shows selective interest ahead of clinical and partnership updates. Fundamentals remain mixed: FY 2024 revenue grew 53.97%, but EPS is -0.28 and important ratios such as P/S 3.64 and P/B 3.78 reflect premium biotech multiples. Meyka AI’s model projects €5.60 in 12 months, implying 61.39% upside, while the quarterly target €4.06 suggests near-term upside of 17.01%. Traders should weigh the company’s cash per share €1.90 and debt-to-equity 0.92 against binary clinical risk. For intraday and short-term positions we recommend watching trial-related phrasing, volume on the print, and updated guidance. Meyka AI — our AI-powered market analysis platform — flags that outcomes can swing valuation sharply. Forecasts are model-based projections and not guarantees; this is market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.